Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Conferences

BIO-Europe Spring 2011: Harry Glorikian presents "Breaking Ground in Personalized Medicine: What Do the Recent Deals Mean for Drug Development?"

Topic

Parallel Panel Discussions - Business Development Track
"Personalized Medicine" seems to be the buzzword for the life science industry. Though for a while it was mainly seen as a threat to their blockbusters, pharma companies are now realizing that the shift towards personalized medicine will happen, and that they must adapt accordingly. Recent deals reflect the rising emphasis of companion diagnostics and biomarkers in drug development, but many questions still go unanswered. Who will be setting benchmarks and dictating the deal terms around personalized medicine, pharma or diagnostics? Which other healthcare players will be involved? Are there viable business models for companion diagnostics today? In lieu of a reliable crystal ball, this panel will take a close look at recent deals around personalized medicine and discuss how these deals are leading the way into a new era in life sciences.

Panelists

• Harry Glorikian - Managing Partner, Scientia Advisors
• Gabriela Lavezzari - Senior Manager, Extramural R&D, Medco Research Institute
• Richard Watts - Director Pharma Business Development, QIAGEN

More information at the Bio-Europe Spring 2011 Website.

Loading video...